Skip to content.

Medicenna Therapeutics closes C$20 million investment from RA Capital Management

Date Closed

April 30, 2024

Lead Office

Québec City


20.00 Million CAD

On April 30, 2024, Medicenna Therapeutics ("Medicenna") closed its previously announced C$20 million investment by RA Capital Management, by way of a non-brokered private placement. Medicenna plans to use the proceeds from the offering for the development of its MDNA11 program, advancement of its preclinical programs, and general corporate purposes.

Medicenna is a clinical-stage immunotherapy company headquartered in Toronto, Ontario, focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and Empowered Superkines.

RA Capital Management is a multi-stage investment manager headquartered in Boston, Massachusetts.

McCarthy Tétrault advised Medicenna with a team led by Charles-Antoine Soulière that included Laurence Cromp-Lapierre, Asma Boudoukha, Annie Poirier-Simard (Business), Christian Meighen and Geneviève Favreau (Tax).